A Reader’s Checklist for GLP-1 Medical Claims

A GLP-1 advertisement can put three very different things next to one another: a published trial result, a description of a telehealth service and a promise about a particular formulation. Their proximity does not establish a connection. A randomized trial may document weight change with a studied medicine, while the adjacent offer concerns a compounded preparation, a different route or a program that has not published its own outcomes. The essential reading skill is identifying where the evidence ends and the sales inference begins.

This checklist uses original trials, federal health guidance and public documentation from six services to show how to separate those questions. The pages were consulted October 19, 2026; that does not mean every page was updated then. The goal is not to choose treatment or rank providers. It is to help U.S. adults ask precise questions about population, intervention, comparator, duration, endpoints, harms, funding and source type before treating a medical claim as applicable to their own care.

At a glance

Population matters: STEP 1 and SURMOUNT-1 studied adults with obesity or overweight plus a weight-related condition or complication, without diabetes. Their findings do not automatically apply to other populations.
Sources: [3] [4]
Match the intervention: Neither trial establishes outcomes for a reviewed provider, its compounded formulations, microdosing programs or other routes.
Sources: [3] [4]
Approval is product-specific: Compounded preparations are not FDA approved. FDA recommends their use when an individual’s medical needs cannot be met by an approved drug; nonapproval alone does not establish clinical inequivalence.
Sources: [1]
Testimonials have a source type: Ro discloses that members were paid for their testimonials. Those accounts are not a substitute for controlled clinical outcomes.
Sources: [18]
Quality claims need their own documentation: Found says its compounded semaglutide is third-party tested for potency, purity and sterility. The consulted documentation did not identify the testing laboratory or provide certificates of analysis.
Sources: [13]

Start by classifying the source, not the headline

Ask first what kind of document supports the claim. An original randomized trial can answer a defined treatment question. FDA guidance explains regulatory and safety concerns. A provider’s FAQ documents what the business says it offers, not whether its patients achieve trial-level results. A testimonial describes an account selected for presentation, not a controlled comparison. Our guide to separating marketing from trial evidence develops this distinction: a true statement about a medicine can still be used to imply something unproven about a service.

Provider documentation remains valuable when read within those limits. Ro discloses paid testimonials. Found describes third-party testing of compounded semaglutide, but the consulted pages do not supply the laboratory’s identity or certificates. Enhance.MD identifies its clinical team as U.S.-licensed physicians and nurse practitioners; that is a provider statement, not an independent credential check. These sources answer different questions. Record both the claim and the type of verification available rather than assigning every polished statement the same evidentiary weight.

Match the document to the question it can reasonably answer
Source type	Useful for	Does not establish
Original randomized trial	Effects of a specified intervention against its comparator	Outcomes at a telehealth provider not studied
FDA public guidance	Regulatory distinctions and reported safety concerns	A provider-specific adverse-event rate
Provider FAQ or terms	Advertised process, responsibilities and restrictions	Independent proof of clinical effectiveness
Testing statement	What testing a provider says occurs	Verified results without supporting records
Paid testimonial	A disclosed promotional account	Typical results or causal treatment effects

Sources: [3] [4] [1] [18] [13] [9]

Population: who was actually studied?

The population is part of the result, not a footnote. STEP 1 enrolled 1,961 adults with obesity or overweight plus a weight-related condition, without diabetes. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus a weight-related complication, also excluding diabetes. A claim that drops those boundaries becomes broader than the evidence. Ask whether the advertised benefit concerns the same health circumstances, and whether the source actually studied the population described in the advertisement.

Provider entry criteria are a separate issue. Enhance.MD advertises a minimum BMI of 25 for new GLP-1 patients and 20 for certain maintenance patients, with medical history also considered. Sesame describes ideal medication candidates as having BMI of at least 30, or at least 27 with weight-related conditions. CoreAge Rx treats adults 18 and older and says availability varies by state, therapy and medicine. These are documented service criteria, not proof that every admitted patient matches a trial population or should expect its average outcome.

Sources: [3] [4] [2] [9] [19] [10]

Intervention: match formulation, route and presentation

Write down exactly what participants received before borrowing a trial’s conclusion. The studied subcutaneous injections in STEP 1 and SURMOUNT-1 do not establish results for oral products, microdoses, vitamin blends or combinations. CoreAge Rx markets semaglutide and tirzepatide microdosing programs and says its compounded tirzepatide is typically formulated with B-12. Enhance.MD markets Elite as an injectable combination of semaglutide and tirzepatide. Those descriptions identify offerings; they do not provide trial evidence for those particular regimens.

The same discipline applies to regulatory language. FDA approval belongs to a specific product, not a platform, clinician group or pharmacy. Compounded preparations lack FDA approval and premarket review for safety, effectiveness and quality. That absence alone establishes neither equivalence nor inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. For a fuller distinction, see approved medicines and compounded preparations.

Sources: [3] [4] [1] [11] [12] [10] [20]

Comparator: better than what?

A claim of effectiveness needs a reference point. STEP 1 compared semaglutide with placebo, and both groups received lifestyle intervention. SURMOUNT-1 also used a placebo comparator. Neither trial randomized patients between the telehealth businesses discussed here. Nor does comparing their headline percentages create a randomized head-to-head comparison between medicines. Our STEP 1 reading guide explains why the comparator and shared background care belong in any useful summary of that study.

This matters when commercial language implies superiority. Enhance.MD presents Advanced for people seeking stronger appetite control and Elite for people who have plateaued on other GLP-1 medicines. Those are provider descriptions of intended positioning, not controlled evidence that the programs outperform alternatives. A useful response is to ask for the exact comparison: the same formulation versus which treatment, in which population, over what period? If no comparative study is documented, the claim remains commercial positioning rather than a demonstrated advantage.

Sources: [3] [4] [15] [20]

Duration and endpoints: attach the clock to the outcome

STEP 1 followed participants for 68 weeks; SURMOUNT-1 for 72 weeks. A result at either endpoint is not a promise about the first month, a delivery date or maintained weight after stopping treatment. Also identify what was measured: average percentage weight change is not the same claim as improved longevity or an individual probability of success. NIDDK describes obesity as a chronic disease that may require long-term care, with treatment duration depending on response and side effects.

Commercial clocks can create a misleading sense of comparable precision. Ro advertises an eligibility decision within two days, while its insurance coordination documentation gives a separate estimate of one to three weeks. CoreAge Rx estimates approximately 24 hours for medical feedback, but its policy separates processing from approximately two to three business days of transit after pharmacy shipment. These are access milestones, not clinical endpoints. Likewise, a package’s advertised duration does not itself establish the quantity supplied or how long a patient must remain enrolled.

Sources: [3] [4] [2] [18] [16] [10] [7]

Harms: read tolerability alongside benefit

An effectiveness summary is incomplete without tolerability. STEP 1 reported discontinuation because of gastrointestinal events, and SURMOUNT-1 identified gastrointestinal events as the most common adverse events and reported adverse-event discontinuations. Those findings concern the studied interventions, not a clinic’s own event rate. FDA also cautions that adverse-event reports lack a denominator for calculating rates and do not automatically establish causation. Neither an alarming report count nor a reassuring absence of published provider data can supply a reliable comparison.

Practical safety responsibilities deserve equally specific questions. FDA has received reports of measurement or administration errors with compounded medicines, some associated with hospitalization; instructions should be clarified with the prescriber or pharmacist rather than reconstructed from an article. FDA explicitly recommends not using injectable GLP-1 medicine that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. A shipping reassurance should not override that advice. Ask who handles the concern and what documentation is available for the actual formulation received.

Sources: [3] [4] [1]

Funding and follow-up: identify interests and responsibilities

Funding belongs in an evidence summary because it identifies a relevant interest, not because it automatically invalidates a study. Novo Nordisk funded STEP 1; Eli Lilly funded SURMOUNT-1. Read that information alongside randomization, comparator, population and harms. The same transparency principle applies to paid testimonials and provider-authored quality claims. Ask what independent documentation is available and whether the evidence concerns the product being offered, rather than treating either commercial involvement or professional branding as a shortcut to a verdict.

Then identify who delivers ongoing care. Found says it follows compounded-tirzepatide patients monthly and offers messaging between visits. Ro lists individual messaging, check-ins, coaching and laboratory testing when necessary within its membership, while excluding medication cost. Walgreens says most follow-up visits occur through chat and separately advertises 24/7 pharmacy-expert chat. That pharmacy channel may involve waiting and is not emergency care or a substitute for physician advice. It should not be read as guaranteed immediate prescriber access or evidence that clinician chat visits carry no charge.

Sources: [3] [4] [18] [5] [13] [6] [14] [17]

Build a claim record before making a decision

For any consequential claim, save its wording and record eight items: population, exact intervention, comparator, duration, endpoint, harms, funding and source type. Add one final question: what part of this evidence concerns the provider itself? Our guide to what provider documents can prove helps distinguish an advertised service feature from independent validation. An unanswered item is not proof that a service lacks it; it is a reason to seek clarification before relying on the claim.

Documentary contradictions are worth preserving too. CoreAge Rx’s FAQ promises a full refund if a prescription is not approved, while its policy retains an applicable $50–$100 consultation fee. Sesame’s program page describes cancellation before the next cycle, but general terms require at least 48 hours’ notice before renewal processing. Neither conflict establishes clinical performance. Both show why favorable language should be checked against other documents, with unresolved conditions confirmed in writing rather than silently reconciled by the reader.

Sources: [10] [7] [19] [8]

Questions & answers

Does CoreAge Rx’s B-12 formulation inherit tirzepatide trial results?

Not automatically. CoreAge Rx says its compounded tirzepatide typically contains B-12 and that an alternative without B-12 can be discussed during intake. SURMOUNT-1 does not establish outcomes for that provider’s blend. Ask for evidence specific to the offered formulation and the reason it is proposed; the shared ingredient name does not close the evidence gap.

Sources: [10] [4]

How should I read Ro’s member success stories?

Ro discloses that participating members were paid for testimonials. That disclosure is useful, but the stories still do not establish typical outcomes, a comparison group or the contribution of the service itself. Read them as promotional accounts, separate from original medicine trials and from Ro’s documented membership features.

Sources: [18] [3] [4]

Does Enhance.MD’s Elite positioning establish stronger results?

No comparative evidence for that conclusion is established here. Enhance.MD markets Elite as an injectable semaglutide-and-tirzepatide combination for people who have plateaued or seek stronger control. The original trials discussed here do not test that combination. Request research matching the combination, population and comparator rather than combining separate trial findings.

Sources: [20] [3] [4]

Does Sesame’s same-day pharmacy language mean immediate treatment?

Sesame advertises same-day local pickup if medication is prescribed, or home delivery instead. Its terms also state that prescribing depends on the professional’s judgment and is not guaranteed. The pickup statement is not a measured clinical outcome or a guarantee of local inventory, immediate evaluation or same-day home arrival.

Sources: [19] [8]

Is Walgreens’ pharmacy chat the same as prescriber follow-up?

No. Walgreens advertises pharmacy-expert chat around the clock, with possible waiting and explicit limits concerning emergencies and medical advice. Its Weight Management documentation separately describes clinician follow-up visits. Initial visits start at $49; follow-up chat visits and additional video visits are $49 each, without a subscription, and medication is separate.

Sources: [17] [14]

What does Found’s third-party testing claim establish?

It establishes that Found publicly says compounded semaglutide undergoes potency, purity and sterility testing before shipment. The consulted documentation does not provide certificates or identify the laboratory. Ask what records apply to the dispensed product. Testing claims also answer different questions from randomized evidence of clinical benefit or FDA product approval.

Sources: [13] [1] [3]

Our assessment

The strongest GLP-1 claim is one whose boundaries remain visible: a defined population, exact intervention, appropriate comparator, stated duration, meaningful endpoint and candid account of harms and funding. Original trials provide important evidence, but they do not certify a telehealth company or validate every formulation it markets. Provider documents are useful for understanding offerings and responsibilities, even when independent outcome evidence is absent. Keep those evidence categories separate, preserve unresolved contradictions and take specific questions to the treating clinician or dispensing pharmacist. That approach supports informed preparation without promising a prescription, a particular result or a universally best provider.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

A Reader’s Checklist for GLP-1 Medical Claims

At a glance

01Start by classifying the source, not the headline

02Population: who was actually studied?

03Intervention: match formulation, route and presentation

04Comparator: better than what?

05Duration and endpoints: attach the clock to the outcome

06Harms: read tolerability alongside benefit

07Funding and follow-up: identify interests and responsibilities

08Build a claim record before making a decision